Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 39Pancreatic Neoplasms 27Rectal Neoplasms 21Stomach Neoplasms 20Colonic Neoplasms 16Esophageal Neoplasms 11Neoplasm Metastasis 7Lymphoma, Large B-Cell, Diffuse 7Gastrointestinal Neoplasms 7Ovarian Neoplasms 6Esophageal Squamous Cell Carcinoma 5Carcinoma, Non-Small-Cell Lung 5Biliary Tract Neoplasms 5Adenocarcinoma Of Esophagus 5Liver Neoplasms 4Cholangiocarcinoma 4Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Gallbladder Neoplasms 3Endometrial Neoplasms 3Advanced Solid Tumors 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Leukemia, Prolymphocytic 2Glioblastoma 2Gastrointestinal Diseases 2Diabetes Mellitus, Insulin-Dependent, 12 2

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1durvalumab 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Cancer × Oxaliplatin × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡